Myasthenia Gravis – Unmet Need – Unmet Need – Generalized Myasthenia Gravis (US/EU)

Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often involves anti-acetylcholine receptor (antiAChR) or antiMuSK antibodies, though some patients remain seronegative and may present with ocularonly symptoms. The FDA, EC, and MHRA have approved six therapies for MG: eculizumab (Alexion / AstraZeneca’s Soliris, biosimilars), efgartigimod (Argenx’s Vyvgart / Vyvgart Hytrulo / SC), ravulizumab (Alexion / AstraZeneca’s Ultomiris), zilucoplan (UCB’s Zilbrysq), rozanolixizumab (UCB’s Rystiggo), and nipocalimab (Johnson & Johnson’s Imaavy). This report examines how key clinical (e.g., change in QMG, MG-ADL, and MGC) and nonclinical (i.e., patient out-of-pocket cost) attributes influence neurologists’ prescribing decisions. It also identifies the key opportunities in the treatment of generalized MG that will be crucial to the strategic positioning of novel agents in this evolving market.

Questions answered

• What are the most important factors driving neurologists’ prescribing decisions for gMG? Do these factors differ between U.S. and European neurologists?
• When considering eculizumab, efgartigimod, ravulizumab, zilucoplan, rozanolixizumab, and nipocalimab, which drug attributes are key influencers, which have limited impact, and which are the hidden opportunities in gMG?
• What are the prevailing areas of unmet need and opportunity in the gMG market?
• What trade-offs are surveyed neurologists willing to make across key clinical attributes and price when considering a new MG therapy?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 34 European neurologists fielded in January 2026

Key drugs: Eculizumab, nipocalimab, rozanolixizumab

Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.